IBRX $243M Cash + No IL15 Competitors = Moonshot

Описание: Not financial advice, entertainment only.
Quick TA scan on $IBRX to set the stage, then straight into the meat: dissecting a fresh X tweet calling out the IL-15 landscape and cash position.

I fed the key claims (competitors? dilution risk? $243M war chest?) directly to AI for a no-BS validity check — spoiler: the response came back bullish, with the moat looking solid and fundamentals stacking up nicely.

This is the contrarian biotech setup of early 2026: ImmunityBio sitting pretty with real cash, ANKTIVA's unique IL-15 superagonist positioning (no crowded comps like PD-1 hell), and multiple shots on goal ahead. Minimal fluff — charts, tweet screenshot, raw AI output, and why this could re-rate hard once the market stops sleeping on it.

Timestamps below.
0:00 - Summary/Opening Technical Analysis (TA) first: Chart walkthrough — price action, key levels, support/resistance, volume, potential breakout signals, macro context (biotech sector sentiment)
1:30 – Technicals and levels
3:30 – 10:00 Deep dive on the tweet claims via AI query: Breaking down IL-15 competitor landscape (why no real threats to ANKTIVA/nogapendekin), cash position validation ($243M confirmed runway, burn rate, recent financing impact), AI's step-by-step reasoning and final verdict — "things looking good" / bullish confirmation
5:30 - Synthesis: How the TA + tweet + AI output combine into the moonshot case, pipeline optionality reminder (expansions, combos, readouts).


Not advice, just one ghost's view. DYOR, size responsibly. #IBRX #Biotech #ANKTIVA #DeepValue #IL15Timestamps (add these manually in YouTube Studio for better engagement/watch time):0:00 Intro & thesis hook: Why revisit IBRX now? Quick overview of the asymmetric setup